OCX (OncoCyte) Year-over-year net earnings per share growth for the last 12 months

Graphic logo of OncoCyte Corporation (OCX)

The OncoCyte Corporation (OCX) monitoring ecosystem relies on B2B relationships and Medicare support, which determines the quarterly EPS dynamics profile. The value of 77.00 expresses the metric level, balancing costs and revenues. Stability is ensured by patents for transplant diagnostics and strict FDA oversight, while profit growth is supported by high-precision Determa tests for lung cancer detection in specialized centers.

oncocyte.com (OCX) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 06/18/2025

Summary analytical data breakdowns for oncocyte.com (OCX)

- market value and analyst target forecast:
- business market valuation indicators:
Comprehensive company analysis:OncoCyte Corporation
Manufactured product of OncoCyte Corporation

The indicator calculates the daily dynamics of quarterly net income per share changes, neutralizing time gaps between official reports for the real-time monitoring of fundamental momentum. For OncoCyte Corporation (OCX), the efficiency of automated genetic analysis and diagnostic robotics translates directly into financial results, allowing the business's scalability to be tracked via the current quarterly EPS growth rate.